- Home
- SCYX vs DRIO Comparison
SCYX vs DRIO Comparison
Compare SCYX & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- DRIO
- Stock Information
- Founded
- SCYX 1999
- DRIO 2011
- Country
- SCYX United States
- DRIO United States
- Employees
- SCYX N/A
- DRIO N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- DRIO Medical/Dental Instruments
- Sector
- SCYX Health Care
- DRIO Health Care
- Exchange
- SCYX Nasdaq
- DRIO Nasdaq
- Market Cap
- SCYX 28.5M
- DRIO 30.5M
- IPO Year
- SCYX 2014
- DRIO N/A
- Fundamental
- Price
- SCYX $0.82
- DRIO $0.70
- Analyst Decision
- SCYX
- DRIO Strong Buy
- Analyst Count
- SCYX 0
- DRIO 2
- Target Price
- SCYX N/A
- DRIO $2.50
- AVG Volume (30 Days)
- SCYX 176.2K
- DRIO 124.6K
- Earning Date
- SCYX 08-07-2025
- DRIO 08-07-2025
- Dividend Yield
- SCYX N/A
- DRIO N/A
- EPS Growth
- SCYX N/A
- DRIO N/A
- EPS
- SCYX N/A
- DRIO N/A
- Revenue
- SCYX $2,630,000.00
- DRIO $28,034,000.00
- Revenue This Year
- SCYX $463.61
- DRIO $13.66
- Revenue Next Year
- SCYX $310.80
- DRIO $24.50
- P/E Ratio
- SCYX N/A
- DRIO N/A
- Revenue Growth
- SCYX N/A
- DRIO 47.20
- 52 Week Low
- SCYX $0.66
- DRIO $0.50
- 52 Week High
- SCYX $2.29
- DRIO $1.55
- Technical
- Relative Strength Index (RSI)
- SCYX 57.87
- DRIO 49.45
- Support Level
- SCYX $0.67
- DRIO $0.67
- Resistance Level
- SCYX $0.75
- DRIO $0.74
- Average True Range (ATR)
- SCYX 0.04
- DRIO 0.03
- MACD
- SCYX 0.01
- DRIO 0.00
- Stochastic Oscillator
- SCYX 93.53
- DRIO 42.86
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.